View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by Central Archive at the University of Reading

Encapsulation of Bifidobacterium longum in alginate-dairy matrices and survival in simulated gastrointestinal conditions, refrigeration, cow milk and goat milk

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Prasanna, P. H. P. and Charalampopoulos, D. (2018) Encapsulation of Bifidobacterium longum in alginate-dairy matrices and survival in simulated gastrointestinal conditions, refrigeration, cow milk and goat milk. Food Bioscience, 21. pp. 72-79. ISSN 2212-4292 doi: https://doi.org/10.1016/j.fbio.2017.12.002 Available at http://centaur.reading.ac.uk/74692/

It is advisable to refer to the publisher's version if you intend to cite from the work. See Guidance on citing.
Published version at: http://dx.doi.org/10.1016/j.fbio.2017.12.002
To link to this article DOI: http://dx.doi.org/10.1016/j.fbio.2017.12.002

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement.

University of Reading

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Encapsulation of *Bifidobacterium longum* in alginate-dairy matrices and survival in simulated gastrointestinal conditions, refrigeration, cow milk and goat milk

Running title: Encapsulation of bifidobacteria in alginate-dairy based matrices

P.H.P. Prasanna [a, b*], D. Charalampopoulos [a]

[a] Department of Food and Nutritional Sciences, University of Reading, Whiteknights, Reading, RG6 6AP, UK

[b] Department of Animal and Food Sciences, Faculty of Agriculture, Rajarata University of Sri Lanka, Puliyankulama, Anuradhapura, Sri Lanka

*Corresponding author:

P.H.P. Prasanna

Department of Animal and Food Sciences, Faculty of Agriculture, Rajarata University of Sri Lanka, Puliyankulama, Anuradhapura, Sri Lanka.

Tele:0094714458656

Fax:0094252221614

Email:phpprasanna@yahoo.com

24 # Abstract

25 The aim of this study was to microencapsulate *Bifidobacterium longum* subsp. *infantis* CCUG
26 52486 using the extrusion method in a variety of matrices, namely sodium alginate (SA),
27 sodium alginate-cow milk (SACM), sodium alginate-goat milk (SAGM) and sodium alginate-
28 casein hydrolysate (SACH), and to evaluate the survival of free and encapsulated bacterial cells
29 under different conditions. The encapsulation yield, size and surface morphology of the
30 microcapsules were evaluated. The survival of microencapsulated bacterial cells and free
31 bacterial cells were evaluated under simulated gastrointestinal conditions as well as in
32 refrigeration, cow milk and goat milk during storage at 4 ºC for 28 days. The average size of
33 SACM capsules and SAGM capsules was 2.8±0.3 mm and 3.1±0.2 mm respectively. Goat
34 milk and cow milk based matrices resulted in dense microcapsules which led to better
35 performances in simulated gastrointestinal conditions than SA and SACH microcapsules. The
36 bacterial cells encapsulated in SAGM showed the highest survival rate in cow milk (7.61 log
37 cfu g^{-1}) and goat milk (8.10 log cfu g^{-1}) after the storage of 28 d. The cells encapsulated in SA
38 and SACH and the free cells performed poorly under the simulated gastrointestinal conditions
39 and in all different storage conditions. This study showed that SACM and SAGM are suitable
40 to encapsulate *B. longum* subsp. *infantis* CCUG 52486 using the extrusion technique and more
41 specifically, SAGM has a potential to be used as a new encapsulation material for
42 encapsulating probiotic bacteria, resulting milk and goat milk-based products with higher
43 probiotic cell concentrations during refrigerated storage.

44

45 *Keywords:* Encapsulation; *Bifidobacterium*; Cow milk; Goat milk; Survival, Refrigeration

46

1. Introduction

Bifidobacteria are a major group of probiotic microorganisms, which have been widely researched for their probiotic properties. Bifidobacteria are considered to exert many beneficial effects to the human host such as alleviation of lactose intolerance, reduction of serum cholesterol levels, synthesis of some vitamins, prevention of colonization of pathogens, modulation of the immune system, reduction of symptoms of irritable bowel disease, and prevention of diarrhoea (Shah, 2007; Xiao et al., 2003). They have been shown to be suitable for incorporation as a co-starter in different food products including dairy-based food formulations (Bunesova et al., 2015; Prasanna et al., 2014). The therapeutic concentration of probiotic bacteria in a product should be around 6 log CFU g−1 until the end of their shelf life (Donkor et al., 2006). In addition, bifidobacteria must endure the high acidic condition in the stomach and hydrolytic enzymes and bile salts in the small intestine prior to reaching the colon in large quantities, which is essential for effective permanent or transient colonization of bacteria (Song et al., 2013). Furthermore, most strains of bifidobacteria show poor growth and viability in milk and fermented milk products (Ranadheera et al., 2014).

In this context, microencapsulation has been widely researched to create a physical barrier protecting the bacteria from adverse conditions during production processes and digestion (Fritzen-Freire et al., 2012). There are many microencapsulation techniques which have been used with probiotics such as emulsion, extrusion, spray drying, freeze drying, coacervation, fluidized bed coating and phase separation (Rajam et al., 2012). Most of these techniques involve harsh processing conditions, which directly affect the viability and the performances of the encapsulated probiotic bacteria. However, the extrusion method involves mild conditions during probiotic encapsulation (Shi et al., 2013a). In this method, a hydrocolloid solution containing concentrated probiotic bacteria is dropped into a solidifying solution. Sodium alginate obtained from brown seaweed has been widely researched as an encapsulation material for probiotics. However, alginate cannot protect effectively probiotic bacteria from the highly acidic environment due to the porous structure of alginate beads, which supports the easy diffusion of acid and other materials inside (Rajam et al., 2012). Therefore, it is recommended to blend or coat alginate with other filler materials to overcome the above-mentioned disadvantages (Cook et al., 2013).

79 Many studies have reported the effectiveness of different alginate based matrices for
80 microencapsulation of probiotic, such as alginate-starch (Sultana et al., 2000), alginate-
81 chitosan (Chávarri et al., 2010; Krasaekoopt et al., 2004), alginate-gelatin (Li et al., 2009),
82 alginate-pectin (Sandoval-Castilla et al., 2010) and alginate-whey protein (Gbassi et al., 2009).
83 In addition, there has been a considerable interest in using dairy-based matrices to encapsulate
84 probiotic bacteria, since these materials contain lactose and proteins which can provide good
85 protection for cells during the handling and digestion process (Maciel et al., 2014). Milk and
86 milk proteins are used in many food formulations and are widely accepted by consumers due
87 to unique physicochemical properties. In the context of encapsulation, milk and milk proteins
88 have technological properties such as high buffering capacity, good emulsification properties
89 and the ability to make networks, even at low concentration (Würth et al., 2015). In addition,
90 it is reported that microcapsules containing dairy proteins can lead to higher bacterial survival
91 during digestion (Burgain et al., 2014). Furthermore, usage of milk based materials for
92 encapsulation of microorganisms would be suitable to be used in dairy-based food products
93 with improved physicochemical properties (Ranadheera et al., 2016). Therefore, there is a high
94 potential to use different milk types and milk based proteins with alginate to encapsulate,
95 protect and control the release of probiotic bacteria in the digestive tract (Özer et al., 2009;
96 Ranadheera et al., 2015).

97 However, there are few recorded reports on the effect of different alginate-dairy based matrices
98 on encapsulation of bifidobacteria. In addition, to the best of authors' knowledge goat milk has
99 not been used with alginate to encapsulate bifidobacteria using the extrusion technique.
100 Therefore, the aim of this study was to evaluate the survival of *Bifidobacterium longum* subsp.
101 *infantis* CCUG 52486 encapsulated in sodium alginate, sodium alginate-cow milk, sodium
102 alginate-goat milk and sodium alginate-casein hydrolysate in simulated gastrointestinal
103 conditions and during storage in cow milk, goat milk and refrigeration at 4 ºC for 28 days. This
104 *Bifidobacterium* strain was selected as in our previous studies, it was shown to produce an
105 exopolysaccharide (EPS) in milk (Prasanna et al., 2012) and to improve the physicochemical
106 and rheological properties of low-fat set yoghurt (Prasanna et al., 2013). In addition, this strain
107 has been characterized as a probiotic strain (Gougoulias et al., 2008) and to have a high a high
108 angiotensin-I-converting enzyme (ACE) inhibitory activity in fermented milk (Gonzalez-
109 Gonzalez et al., 2011)

110

111 ## 2. Materials and methods

112 *2.1. Bacterial strain and growth conditions*

113 *B. longum* subsp. *infantis* CCUG 52486 was obtained from the culture collection of the
114 University of Göteborg in Sweden. The cell bank of microorganism was stored at −80 °C in
115 Wilkins-Chalgren (WC) anaerobe broth (Oxoid, Hampshire, UK) containing 15% (v/v)
116 glycerol. The frozen stock was initially propagated in Bifidobacteria Selective Medium (BSM)
117 agar (Sigma-Aldrich, Dorset, UK) under anaerobic conditions at 37 °C for 72 h. Two
118 successive cultures of bacteria were carried out in WC broth (Oxoid, UK) under anaerobic
119 condition at 37 °C for 18 h. Subsequently, a cell aliquot of the preculture (1%, v/v) was used
120 to inoculate 200 mL of WC broth (Oxoid, UK) and incubated at 37 °C for 18 h under anaerobic
121 condition. Bacterial cells were harvested after by centrifugation at 10,000 rpm for 10 min at 4
122 °C. The pellet was washed with sterile phosphate buffered saline (PBS) (Oxoid, UK) and
123 aseptically resuspended in 10 mL of PBS (Oxoid, UK) to prepare the concentrated cell
124 suspension.

125

126 *2.2. Encapsulation of B. longum subsp. infantis CCUG 52486*

127 Sterilized cow milk and sterilized goat milk were purchased from a local supermarket. Casein
128 hydrolysate solution (2%, w/v, Sigma-Aldrich, UK) and sodium alginate solution (2%, w/v,
129 low viscosity, Sigma-Aldrich, UK) were sterilized at 121 °C for 15 min. Three different
130 alginate-dairy based microsphere formulations were prepared. They were SACM (sodium
131 alginate/cow milk = 1.5/1, v/v), SAGM (sodium alginate/goat milk = 1.5/1, v/v) and SACH
132 (sodium alginate/casein hydrolysate = 1.5/1, v/v); SA (sodium alginate) was used as the
133 control. Each alginate-based formulation was mixed with the concentrated cell suspension at a
134 ratio of 4:1 (alginate-based mixture solution: the concentrated cell suspension, v/v). In the case
135 of free cells, 10 mL of the concentrated cell suspension was mixed with 40 mL of PBS (Oxoid,
136 UK). The hydrocolloid-cell suspensions were dropped through a 21G needle into sterile 0.1 M
137 $CaCl_2$ (Sigma-Aldrich, UK) under gentle stirring; the dropping height was 10 cm.
138 Microcapsules were allowed to harden for 30 minutes and were then washed with sterile PBS
139 (Oxoid, UK) and stored in sterilized plastic containers at 4 °C. The cell concentration
140 encapsulated in the microcapsules was around 9 log cfu g^{-1}.

141

142 *2.3. Determination of encapsulation yield and size of alginate–milk microcapsules*

143 The encapsulation yield (EY) was determined using the following equation. EY = (Number of
144 cells released from microcapsules) / (Number of cells added to the respective alginate based
145 microsphere formulation) X 100. The size of different microcapsules was measured using a
146 vernier caliper. For this, 30 microcapsules were randomly selected from each microsphere
147 formulation to calculate the mean size.

148

149 *2.4. Determination of viability of free and encapsulated bacteria*

150 Samples of free *B. longum* subsp. *infantis* cells were serially diluted in PBS (Oxoid, UK) and
151 100 µL aliquots were plated on BSM agar (Sigma-Aldrich, UK) to enumerate the viable
152 bacterial counts. The plates were incubated under anaerobic conditions at 37 °C for 72 h. In
153 the case of encapsulated bacteria, the samples were completely dissolved in sterilized 50 mM
154 sodium citrate (Sigma-Aldrich, UK) solution at pH 7.5 before plating as described by Shi et al.
155 (2013a). For this, 1 g of the encapsulated bacteria was dissolved in 9 mL sodium citrate and
156 the samples were serially diluted in PBS (Oxoid, UK). Aliquots of 100 µL of the serially diluted
157 sample were plated on BSM agar (Sigma-Aldrich, UK) and after incubation, the viable cell
158 counts were enumerated.

159

160 *2.5. Survival of free and encapsulated bacteria in simulated gastrointestinal conditions*

161 Simulated gastric juice (SGJ) was prepared by dissolving 0.2% NaCl (w/v) in 0.08 M HCl, at
162 pH 2 as described by Sun and Griffiths (2000). The microcapsules (1 g) or the free cells (1 mL)
163 were added to glass tubes containing 9 mL of sterilized SGJ and placed in a water bath at 37
164 ^{o}C. Samples were taken at 0, 30, 60 and 120 min, during incubation. For the free cells, the
165 samples were taken and centrifuged at 10,000 rpm for 10 min, at 4 °C. The pellet was dissolved
166 in PBS (Oxoid, UK) and used for cell enumeration. In the case of microencapsulated bacterial
167 cells, the microcapsules were separated from the samples and dissolved in sodium citrate (50
168 mM) before plating. For enumeration, all samples were serially diluted in PBS (Oxoid, UK)
169 and viable cells were enumerated as described in Section 2.4.

170

171 Simulated intestinal juice (SIJ) was prepared as described by Chávarri et al. (2010). For this, 3
172 g of bile salt (Sigma-Aldrich, UK) were dissolved in 1 L of intestinal model solution (6.5 g/L

173 NaCl, 0.835 g/L KCl, 0.22 g/L $CaCl_2$ and 1.386 g/L $NaHCO_3$), at pH 7.5. Microcapsules (1 g)
174 or the free cells (1 mL) were added to glass tubes containing 9 mL of sterilized SIJ and placed
175 in a water bath at 37 ºC. The sampling and enumeration of free and encapsulated *B. longum*
176 subsp. *infantis* CCUG 52486 were carried out as described previously.

177

178 *2.6. Survival of free and microencapsulated bacterial cells in refrigeration, cow milk and goat*
179 *milk during refrigerated storage*

180 In the case of refrigerated storage, microcapsules or free cells were stored (1 g for
181 microcapsules/ 1 mL for free cells in each portion) in sterilized centrifuge tubes (15 mL
182 capacity, polypropylene, Fisher Scientific, Loughborough, UK), at 4 ºC for 28 days. In the case
183 of cow milk, 1 mL of the free cells or 1 g of the encapsulated bacteria was mixed with 10 mL
184 of sterilized cow milk in sterilized centrifuge tubes (15 mL capacity, polypropylene, Fisher
185 Scientific, UK). In the case of goat milk, 10 mL of sterilized goat milk in sterilized centrifuge
186 tubes (15 mL capacity, polypropylene, Fisher Scientific, UK) were mixed with 1 mL of the
187 free cells or 1 g of the encapsulated cells. The centrifuge tubes containing free and encapsulated
188 bacteria and inoculated milk samples were stored at 4 ºC for 28 days. Afterwards, the samples
189 were collected on 0, 7, 14, 21 and 28 days and analyzed for the viability of cells as described
190 in Section 2.4.

191

192 *2.7. Scanning electron microscopic (SEM) analysis of surface of microcapsules*

193 The microcapsules were dehydrated sequentially in a series of ethanol solutions (30, 50, 70,
194 80, 90, and 100%). For this, the microcapsules were soaked for 15 minutes in each solution.
195 The dehydrated microcapsules were critical point dried using a critical point dryer (Balzers
196 CPD 030, Liechtenstein, Germany) with liquid carbon dioxide. The dried samples were fixed
197 to the SEM stubs with double-sided tape. Afterward, the microcapsules were gold coated using
198 an Edwards S150B sputter-coater for 2.5 min (Edwards, West Sussex, UK). The surface of
199 coated microcapsules was examined using a scanning electron microscope (FEI, Quanta 600
200 F, USA).

201

202 *2.8. Statistical analysis*

203 All the experiments were conducted in triplicate. Results of the size of microcapsules and
204 encapsulation efficiency were analyzed using one-way analysis of variance (ANOVA) with

205 Turkey's multiple comparison tests (SAS, version 9.2, SAS Institute Inc., Cary NC, USA).
206 Results of viable counts from simulated gastrointestinal conditions and from storage studies
207 were analyzed as a split-plot in time design using the General Linear Model (GLM) procedure
208 of SAS, version 9.2 (SAS Institute Inc., Cary NC, USA).

209

210 3. Results and discussion

211 *3.1. Size, encapsulation yield and surface morphology of microcapsules*

212

213 Table *1* shows the size of the different microcapsules. The type of encapsulation material had
214 a significant influence ($p<0.05$) on the size of microcapsules. The largest microcapsules were
215 observed with SAGM while their sizes were not significantly different ($p>0.05$) with those of
216 SACM microcapsules. The smallest microcapsules in this study were observed with SA
217 though, the value was not significantly different with that of SACH. There is no published
218 literature to compare with the size of SAGM microcapsules, which have been prepared using
219 the extrusion technique. Our results showed that the addition of goat milk and cow milk to
220 sodium alginate resulted larger microcapsules than SA and SACH. This may be due to the
221 higher protein content of cow milk and goat milk which, can lead to higher total protein content
222 of SACM and SAGM. Similarly, Klemmer et al. (2011) and Shi et al. (2013a) reported that the
223 higher protein content in matrices could lead to larger microcapsules.

224

225 The type of encapsulating matrices had no significant ($p>0.05$) effect on the encapsulation
226 yield (

227 Table *1*) and the values ranged from 94.1% to 95.6%. Our results are in accordance with
228 findings of Pan et al. (2013) who reported around 99% of the encapsulation efficiency of
229 bacteria with alginate-skim milk. The results clearly showed that there was a very low loss of
230 cell viability during the encapsulation which was due to the mild conditions used. In general,
231 extrusion method is commonly used with hydrocolloids and reported to yield higher
232 encapsulation yield (Krasaekoopt et al., 2003).

233

234 The surface morphology of the microcapsules was investigated using SEM micrographs. Fig.1
235 shows the surface of different microcapsules at a magnification of 10000. Porous
236 microcapsules were observed with SA [Fig.1 (A)]. Furthermore, SA microcapsules had cracks
237 on their surface and could not protect entrapped cells from adverse environmental conditions.
238 Similarly, Li et al. (2009) reported porous structure for microcapsules produced using alginate.
239 Modification of alginate with cow milk and goat milk resulted in the microcapsules (SACM,
240 SAGM) with denser surface morphology [Fig.1 (B) and (C)]. In addition, these microcapsules
241 did not have cracks that could ensure high protection for encapsulated cells from adverse
242 conditions. SACH microcapsules showed irregular surface morphology [Fig.1 (D)] which
243 could not give better protection for entrapped cells than that of SACM and SAGM
244 microcapsules.

245

246 *3.2. Survival of free and encapsulated B. longum subsp. infantis CCUG 52486 in simulated*
247 *gastric juice*

248 Microencapsulation provided a significant protection for the cells in simulated gastric juice
249 (Fig. 2). The viable cell count of free *B. longum* subsp. *infantis* CCUG decreased significantly
250 ($p<0.05$) within 90 min of the incubation period and the cell count of free cells dropped to an
251 undetectable level ($< 10^1$ cfu mL^{-1}) after 120 min. This is because bifidobacteria are fastidious
252 organisms which are sensitive to acidic environment leading to challenges in industrial
253 applications. Similarly, Lee and Heo (2000) observed a rapid reduction of the cell viability of
254 free *B. longum* KCTC 3128 within 30 min when exposed to a simulated gastric environment.
255 The present study also demonstrated that sodium alginate itself could not protect *B. longum*
256 subsp. *infantis* CCUG from the highly acidic environment for a long time. Alginate is a
257 copolymer and composed of D-mannuronic and L-guluronic acids. This copolymer is not stable
258 at low pH condition (Liserre et al., 2007). Dissolution and erosion of alginate occur at low pH

259 and lead for destruction of capsule structure. Our results are in accordance with findings of
260 Krasaekoopt et al. (2004) and who reported poor viability of bacterial cells microencapsulated
261 with alginate in simulated gastric juice. The results clearly showed that microencapsulation
262 with SACM and SAGM gave a better protection for the cells than SA and SACH. The viable
263 cell counts of SACM and SAGM microcapsules were 6.37 log cfu g^{-1} and 5.19 log cfu g^{-1}
264 respectively, after 120 min. The better protection observed in microencapsulated bacterial cells
265 by cow milk and goat milk based matrices may be due to the high buffering capacity of milk
266 proteins. In addition, milk proteins can interact with alginate and act as filling materials which
267 can seal the porous structure of alginate-milk based microcapsules (Kailasapathy, 2006). Our
268 results are in accordance with observations made in some other studies. Guérin et al. (2003)
269 reported that the encapsulated bifidobacteria in a mixed gel made of alginate, pectin and whey
270 proteins could survive better in simulated gastric juice at pH 2.5 due to buffering activities of
271 whey proteins.

272

273 *3.3. Survival of free and encapsulated bacterial cells in simulated intestinal juice*

274 The survival of free and encapsulated *B. longum* subsp. *infantis* CCUG 52486 in simulated
275 intestinal juice at 37 ºC for 2 h is presented in Fig. 3. Encapsulation gave a significant ($p<0.05$)
276 protection for bacterial cells in simulated intestinal juice. The viable count of free cells showed
277 a significant ($p<0.05$) decrease within 120 min. This may be due to the interaction of bile salt
278 with the free cells leading to lose of cell wall integrity. The loss of cell wall integrity may lead
279 to leakage of intercellular materials from the cells leading for death of cells (Bron et al., 2004).
280 Similarly, Clark and Martin (1994) reported a rapid decrease of the viability of free cells of *B.*
281 *adolescentis* in 2% bile salt solution at 37 ºC.

282

283 Milk based microcapsules (SACM and SAGM) were the most effective in protecting the cells
284 in simulated intestinal juice. It is due to milk ingredients, which can modify the textural
285 properties of alginate-milk based matrices [Fig.1 (B) and (C)], as the modified matrices resist
286 the diffusion of bile salt into the microcapsules. Similarly, alginate-milk based matrices were
287 shown to be effective in protection of *Lactobacillus bulgaricus* (Shi et al., 2013a; Shi et al.,
288 2013b) and *Enterococcus faecalis* (Shi et al., 2016) in simulated intestinal solution. SA and
289 SACH microcapsules provided a limited protection for bacterial cells during the incubation
290 period. This is due to the poor structure of those matrices [Fig.1 (A) and (D)], which can allow

diffusion of bile salt into the microcapsules (Hansen et al., 2002; Lee and Heo, 2000). Similarly, Krasaekoopt et al. (2004) reported poor viability of *B. bifidum* ATCC 1994 capsulated in alginate matrices when exposed to bile salt solution.

3.4. Stability of free and encapsulated bacteria cells under refrigerated condition

Fig. 4 shows the viability of free and encapsulated *B. longum* subsp. *infantis* CCUG 52486 with different alginate-based matrices during the refrigerated storage at 4 ^{o}C. The cell concentration of free *B. longum* subsp. *infantis* CCUG 52486 decreased significantly ($p<0.05$) from 8.96 log cfu g^{-1} to 3.62 log cfu g^{-1}, indicating the inability of the free cells to maintain their viability under the refrigerated storage condition. The results further revealed that encapsulation could improve the viability of bacterial cells during refrigerated storage for 28 days. SA and SACH microcapsules showed higher cell viability than that of the free cells during the refrigerated storage. However, they were unable to maintain the viability of cells during the storage above the recommended count of 6 log cfu g^{-1}. Similarly, some studies reported that encapsulation of probiotic bacteria in sodium alginate could improve the storage stability of bacterial cells than that of the free cells (Chávarri et al., 2010; Krasaekoopt et al., 2004).

SACM and SAGM microcapsules gave better protection for the cells during the refrigerated storage and both materials were able to maintain the cell concentrations above 6 log cfu g^{-1} after 28 days of storage than SA and SACH. However, the final cell counts of these two microcapsules were not significantly different ($p<0.05$). This may be due to the denser surface morphology of alginate-dairy microcapsules [Fig.1 (B) and (C)], which can protect the encapsulated cells from adverse conditions of the environment. Similarly, some other alginate-based microcapsules have been shown to be effective to give better protection for probiotics during the refrigerated storage. Encapsulation of *Lactobacillus gasseri* and *B. bifidum* in chitosan-coated alginate microspheres was shown to be effective to maintain viability throughout the storage period at 4 ^{o}C for 28 days (Chávarri et al., 2010). In addition, Zou et al. (2011) showed that chitosan-coated alginate microspheres provided a better protection for the microencapsulated *B. bifidum* F-35 cells than that of the free cells during the storage at 4 ^{o}C for 1 month.

323 *3.5. Survival of free and encapsulated bacterial cells in cow milk and goat milk at 4 °C*

324 Table 2 shows the survival of free and encapsulated stored in cow milk at 4 °C for 28 days.
325 The results indicated that encapsulation improved the survival of bacterial cells in cow milk
326 during storage. The free cells showed poor storage stability in cow milk where the cell
327 concentration was significantly ($p<0.05$) reduced from 8.65 log cfu mL^{-1} to 4.38 log cfu mL^{-1}
328 within 28 days. SAGM microcapsules gave the best protection for the cells followed by SACM
329 microcapsules. However, SA and SACH microcapsules could give a limited protection during
330 the storage in cow milk. Fig. 5 shows the results of free and encapsulated bacterial counts in
331 goat milk during storage at 4 °C for 28 days. There was a significant reduction ($p<0.05$) in the
332 viability of free cells during the storage. However, the results revealed that encapsulation of *B.*
333 *longum* subsp. *infantis* CCUG 52486 improved the survival of bacterial cells in goat milk
334 during the storage period of 28 days. The highest survival of bacterial cells during the storage
335 was observed with SAGM microcapsules followed by SACM microcapsules; where they
336 maintained the viability of bacterial cells above 6 log cfu g^{-1} in goat milk during the storage
337 period. Viable cell counts of SA and SACH microcapsules rapidly declined with the storage.

338

339 Poor viability of free cells in cow milk and goat milk is due to lack of availability of small
340 peptides and free amino acids for their growth (Gomes et al., 1998; Martín-Diana et al., 2003).
341 In this study, pure goat milk and cow milk were used to inoculate bacteria without any
342 supplementation. Similarly, Hansen et al. (2002) observed poor viability of free *B. longum* Bb-
343 46 cells in milk during storage at 4 °C for 16 days than that of encapsulated bacterial cells. The
344 poor survival of bacterial cells encapsulated in SA and SACH is due to the fragile texture of
345 walls of these microcapsules [Fig.1 (A) and (D)], which exposes bacterial cells to the external
346 environment. The high survival rate observed with microencapsulated bacterial cells with
347 SACM and SAGM [Fig.1 (B) and (C)] in cow milk and goat milk may be due to improved
348 denser surface characteristics compared to SA and SACH. The modified structure of SACM
349 and SASM could protect their content form the adverse external environments. There is no
350 recognized published literature about the survival of bifidobacteria encapsulated using
351 alginate-milk based matrices in goat milk during storage to compare with our results. However,
352 some authors have reported that encapsulation can improve the viability of bifidobacteria in
353 cow milk and cow milk-based products. Hansen et al. (2002) showed the effectiveness of
354 alginate microcapsules to improve the viability of *B. longum* Bb-46 in cow milk during the
355 storage at 4 °C for 16 days. In another study, *B. bifidum* encapsulated in alginate beads coated

356 with chitosan was shown to have better survival than the free cell in yoghurt after the storage
357 at 4 °C for 4 weeks (Krasaekoopt et al., 2006). In addition Kailasapathy (2006) showed that the
358 alginate-starch encapsulated *B. lactis* had higher survival than the free cells in yoghurt at 4 °C
359 for 7 weeks.

360

361 The present study demonstrates that encapsulation of *B. longum* subsp. *infantis* CCUG 52486
362 in SACM and SAGM microcapsules beneficially influences the viability of bacterial cells in
363 cow milk and goat milk during the storage at 4 °C for 28 days. Therefore, microencapsulation
364 of bifidobacteria with SACM and SAGM could be used to enhance the growth of them in non-
365 fermented cow milk and goat milk based products. Further studies should be carried out to
366 evaluate the effect of encapsulation of bifidobacteria with SACM and SAGM microcapsules
367 in fermented milk-based products and other food systems.

368

369 4. Conclusions

370 The mixing of alginate with cow milk and goat milk resulted in microcapsules with denser
371 surface and the cells encapsulated in these matrices performed better in simulated
372 gastrointestinal conditions than the bacterial cells encapsulated in SA and SACH
373 microcapsules. Improved structural characteristics of SACM and SAGM microcapsules could
374 improve survival of encapsulated bacterial cells in cow milk, goat milk and refrigeration at 4
375 °C for 28 days compared to SA and SACH microcapsules. Overall, this study showed that
376 mixing of goat milk and cow milk with alginate improved the protection provided by modified
377 microcapsules and could be used to improve survival of probiotic bacteria in non-fermented
378 cow milk and goat milk based products.

379

380 Acknowledgements

381 P.H.P. Prasanna is a Commonwealth Academic Fellow, funded by the UK government. The
382 technical assistance with SEM by the Centre for Advanced Microscopy (CfAM), University of
383 Reading, UK, is greatly acknowledged.

384

385 **References**

386 Bron, P. A., Marco, M., Hoffer, S. M., Van Mullekom, E., De Vos, W. M., & Kleerebezem,
387 M. (2004). Genetic characterization of the bile salt response in *Lactobacillus plantarum*
388 and analysis of responsive promoters in vitro and in situ in the gastrointestinal tract.
389 *Journal of Bacteriology, 186*(23), 7829-7835.

390 Bunesova, V., Musilova, S., Geigerova, M., Pechar, R., & Rada, V. (2015). Comparison of
391 mupirocin-based media for selective enumeration of bifidobacteria in probiotic
392 supplements. *Journal of Microbiological Methods, 109*, 106-109.

393 Burgain, J., Scher, J., Lebeer, S., Vanderleyden, J., Cailliez-Grimal, C., Corgneau, M.,
394 Francius, G., & Gaiani, C. (2014). Significance of bacterial surface molecules
395 interactions with milk proteins to enhance microencapsulation of *Lactobacillus*
396 *rhamnosus* GG. *Food Hydrocolloids, 41*, 60-70.

397 Chávarri, M., Marañón, I., Ares, R., Ibáñez, F. C., Marzo, F., & del Carmen Villarán, M.
398 (2010). Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules
399 improves survival in simulated gastro-intestinal conditions. *International Journal of*
400 *Food Microbiology, 142*(1), 185-189.

401 Clark, P. A., & Martin, J. H. X. (1994). Selection of bifidobacteria for use as dietary adjuncts
402 in cultured dairy foods. III. Tolerance to simulated bile concentrations of human small
403 intestines. *Cultured Dairy Products Journal, 29*, 18-21.

404 Cook, M. T., Tzortzis, G., Khutoryanskiy, V. V., & Charalampopoulos, D. (2013). Layer-by-
405 layer coating of alginate matrices with chitosan-alginate for the improved survival and
406 targeted delivery of probiotic bacteria after oral administration. *Journal of Materials*
407 *Chemistry B, 1*(1), 52-60.

408 Donkor, O., Henriksson, A., Vasiljevic, T., & Shah, N. (2006). Effect of acidification on the
409 activity of probiotics in yoghurt during cold storage. *International Dairy Journal,*
410 *16*(10), 1181-1189.

411 Fritzen-Freire, C. B., Prudêncio, E. S., Amboni, R. D. M. C., Pinto, S. S., Negrão-Murakami,
412 A. N., & Murakami, F. S. (2012). Microencapsulation of bifidobacteria by spray drying
413 in the presence of prebiotics. *Food Research International, 45*(1), 306-312.

414 Gbassi, G. K., Vandamme, T., Ennahar, S., & Marchioni, E. (2009). Microencapsulation of
415 *Lactobacillus plantarum* spp in an alginate matrix coated with whey proteins.
416 *International Journal of Food Microbiology, 129*(1), 103-105.

417 Gomes, A. M. P., Malcata, F. X., & Klaver, F. A. M. (1998). Growth enhancement of
418 *Bifidobacterium lactis* Bo and *Lactobacillus acidophilus* Ki by milk hydrolyzates.
419 *Journal of Dairy Science, 81*(11), 2817-2825.

420 Gonzalez-Gonzalez, C. R., Tuohy, K. M., & Jauregi, P. (2011). Production of angiotensin-I-
421 converting enzyme (ACE) inhibitory activity in milk fermented with probiotic strains:
422 effects of calcium, pH and peptides on the ACE-inhibitory activity. *International Dairy*
423 *Journal, 21*(9), 615-622.

424 Gougoulias, C., Tuohy, K. M., & Gibson, G. R. (2008). Dietary-based gut flora modulation
425 against *Clostridium dificile* onset. *Food Science and Technology Bulletin: Functional*
426 *Foods, 4*(4), 31-41.

427 Guérin, D., Vuillemard, J. C., & Subirade, M. (2003). Protection of bifidobacteria encapsulated
428 in polysaccharide-protein gel beads against gastric juice and bile. *Journal of Food*
429 *Protection, 66*(11), 2076-2084.

430 Hansen, L. T., Allan-Wojtas, P. M., Jin, Y. L., & Paulson, A. T. (2002). Survival of Ca-alginate
431 microencapsulated *Bifidobacterium* spp. in milk and simulated gastrointestinal
432 conditions. *Food Microbiology, 19*(1), 35-45.

433 Kailasapathy, K. (2006). Survival of free and encapsulated probiotic bacteria and their effect
434 on the sensory properties of yoghurt. *LWT-Food Science and Technology, 39*(10),
435 1221-1227.

436 Klemmer, K. J., Korber, D. R., Low, N. H., & Nickerson, M. T. (2011). Pea protein-based
437 capsules for probiotic and prebiotic delivery. *International Journal of Food Science &*
438 *Technology, 46*(11), 2248-2256.

439 Krasaekoopt, W., Bhandari, B., & Deeth, H. (2003). Evaluation of encapsulation techniques of
440 probiotics for yoghurt. *International Dairy Journal, 13*(1), 3-13.

441 Krasaekoopt, W., Bhandari, B., & Deeth, H. (2004). The influence of coating materials on
442 some properties of alginate beads and survivability of microencapsulated probiotic
443 bacteria. *International Dairy Journal, 14*(8), 737-743.

444 Krasaekoopt, W., Bhandari, B., & Deeth, H. C. (2006). Survival of probiotics encapsulated in
445 chitosan-coated alginate beads in yoghurt from UHT-and conventionally treated milk
446 during storage. *LWT-Food Science and Technology, 39*(2), 177-183.

447 Lee, K. Y., & Heo, T. R. (2000). Survival of *Bifidobacterium longum* immobilized in calcium
448 alginate beads in simulated gastric juices and bile salt solution. *Applied and*
449 *Environmental Microbiology, 66*(2), 869-873.

450 Li, X. Y., Chen, X. G., Cha, D. S., Park, H. J., & Liu, C. S. (2009). Microencapsulation of a
451 probiotic bacteria with alginate-gelatin and its properties. *Journal of*
452 *Microencapsulation, 26*(4), 315-324.

453 Liserre, A. M., Ré, M. I., & Franco, B. D. G. M. (2007). Microencapsulation of
454 *Bifidobacterium animalis* subsp. *lactis* in modified alginate-chitosan beads and
455 evaluation of survival in simulated gastrointestinal conditions. *Food Biotechnology,*
456 *21*(1), 1-16.

457 Maciel, G. M., Chaves, K. S., Grosso, C. R. F., & Gigante, M. L. (2014). Microencapsulation
458 of *Lactobacillus acidophilus* La-5 by spray-drying using sweet whey and skim milk as
459 encapsulating materials. *Journal of Dairy Science, 97*(4), 1991-1998.

460 Martín-Diana, A. B., Janer, C., Peláez, C., & Requena, T. (2003). Development of a fermented
461 goat's milk containing probiotic bacteria. *International Dairy Journal, 13*(10), 827-833.

462 Özer, B., Kirmaci, H. A., Şenel, E., Atamer, M., & Hayaloğlu, A. (2009). Improving the
463 viability of *Bifidobacterium bifidum* BB-12 and *Lactobacillus acidophilus* LA-5 in
464 white-brined cheese by microencapsulation. *International Dairy Journal, 19*(1), 22-29.

465 Pan, L. X., Fang, X. J., Yu, Z., Xin, Y., Liu, X. Y., Shi, L. E., & Tang, Z. X. (2013).
466 Encapsulation in alginate–skim milk microspheres improves viability of *Lactobacillus*
467 *bulgaricus* in stimulated gastrointestinal conditions. *International Journal of Food*
468 *Sciences and Nutrition, 64*(3), 380-384.

469 Prasanna, P. H. P., Grandison, A. S., & Charalampopoulos, D. (2012). Effect of dairy-based
470 protein sources and temperature on growth, acidification and exopolysaccharide
471 production of *Bifidobacterium* strains in skim milk. *Food Research International,*
472 *47*(1), 6-12.

473 Prasanna, P. H. P., Grandison, A. S., & Charalampopoulos, D. (2013). Microbiological,
474 chemical and rheological properties of low fat set yoghurt produced with

475 exopolysaccharide (EPS) producing *Bifidobacterium* strains. *Food Research*
476 *International, 51*(1), 15-22.

477 Prasanna, P. H. P., Grandison, A. S., & Charalampopoulos, D. (2014). Bifidobacteria in milk
478 products: An overview of physiological and biochemical properties, exopolysaccharide
479 production, selection criteria of milk products and health benefits. *Food Research*
480 *International, 55*, 247-262.

481 Rajam, R., Karthik, P., Parthasarathi, S., Joseph, G., & Anandharamakrishnan, C. (2012).
482 Effect of whey protein–alginate wall systems on survival of microencapsulated
483 *Lactobacillus plantarum* in simulated gastrointestinal conditions. *Journal of Functional*
484 *Foods, 4*(4), 891-898.

485 Ranadheera, C. S., Evans, C. A., Adams, M. C., & Baines, S. K. (2014). Effect of dairy
486 probiotic combinations on *in vitro* gastrointestinal tolerance, intestinal epithelial cell
487 adhesion and cytokine secretion. *Journal of Functional Foods, 8*, 18-25.

488 Ranadheera, C. S., Evans, C. A., Adams, M. C., & Baines, S. K. (2015). Microencapsulation
489 of *Lactobacillus acidophilus* LA-5, *Bifidobacterium animalis* subsp. *lactis* BB-12 and
490 *Propionibacterium jensenii* 702 by spray drying in goat's milk. *Small Ruminant*
491 *Research, 123*(1), 155-159.

492 Ranadheera, C. S., Liyanaarachchi, W. S., Chandrapala, J., Dissanayake, M., & Vasiljevic, T.
493 (2016). Utilizing unique properties of caseins and the casein micelle for delivery of
494 sensitive food ingredients and bioactives. *Trends in Food Science & Technology,*
495 *57*(Part A), 178-187.

496 Sandoval-Castilla, O., Lobato-Calleros, C., García-Galindo, H., Alvarez-Ramírez, J., &
497 Vernon-Carter, E. (2010). Textural properties of alginate–pectin beads and
498 survivability of entrapped *Lb. casei* in simulated gastrointestinal conditions and in
499 yoghurt. *Food Research International, 43*(1), 111-117.

500 Shah, N. P. (2007). Functional cultures and health benefits. *International Dairy Journal,*
501 *17*(11), 1262-1277.

502 Shi, L. E., Li, Z. H., Li, D. T., Xu, M., Chen, H. Y., Zhang, Z. L., & Tang, Z. X. (2013a).
503 Encapsulation of probiotic *Lactobacillus bulgaricus* in alginate–milk microspheres and
504 evaluation of the survival in simulated gastrointestinal conditions. *Journal of Food*
505 *Engineering, 117*(1), 99-104.

Shi, L. E., Li, Z. H., Zhang, Z. L., Zhang, T. T., Yu, W. M., Zhou, M. L., & Tang, Z. X. (2013b). Encapsulation of *Lactobacillus bulgaricus* in carrageenan-locust bean gum coated milk microspheres with double layer structure. *LWT-Food Science and Technology, 54*(1), 147-151.

Shi, L. E., Zheng, W., Zhang, Y., & Tang, Z. X. (2016). Milk-alginate microspheres: Protection and delivery of *Enterococcus faecalis* HZNU P2. *LWT-Food Science and Technology, 65*, 840-844.

Song, H., Yu, W., Gao, M., Liu, X., & Ma, X. (2013). Microencapsulated probiotics using emulsification technique coupled with internal or external gelation process. *Carbohydrate Polymers, 96*(1), 181-189.

Sultana, K., Godward, G., Reynolds, N., Arumugaswamy, R., Peiris, P., & Kailasapathy, K. (2000). Encapsulation of probiotic bacteria with alginate–starch and evaluation of survival in simulated gastrointestinal conditions and in yoghurt. *International Journal of Food Microbiology, 62*(1–2), 47-55.

Sun, W., & Griffiths, M. W. (2000). Survival of bifidobacteria in yogurt and simulated gastric juice following immobilization in gellan–xanthan beads. *International Journal of Food Microbiology, 61*(1), 17-25.

Würth, R., Hörmannsperger, G., Wilke, J., Foerst, P., Haller, D., & Kulozik, U. (2015). Protective effect of milk protein based microencapsulation on bacterial survival in simulated gastric juice versus the murine gastrointestinal system. *Journal of Functional Foods, 15*, 116-125.

Xiao, J., Kondo, S., Takahashi, N., Miyaji, K., Oshida, K., Hiramatsu, A., Iwatsuki, K., Kokubo, S., & Hosono, A. (2003). Effects of milk products fermented by *Bifidobacterium longum* on blood lipids in rats and healthy adult male volunteers. *Journal of Dairy Science, 86*(7), 2452-2461.

Zou, Q., Zhao, J., Liu, X., Tian, F., Zhang, H., Zhang, H., & Chen, W. (2011). Microencapsulation of *Bifidobacterium bifidum* F-35 in reinforced alginate microspheres prepared by emulsification/internal gelation. *International Journal of Food Science & Technology, 46*(8), 1672-1678.

537

538

539

Figure captions

Fig.1. Scanning electron micrographs showing the surface morphology of different microcapsules. (A) SA, (B) SACM, (C) SAGM, (D) SACH (magnification 10000X). For legend explanations see Table1.

Fig. 2. Survival of free and encapsulated *B. longum* subsp. *infantis* CCUG 52486 in simulated gastric juice (pH 2) at 37 ºC for 120 min. Vertical lines represent standard deviations. ^{ABCDE}Means with different uppercase are significantly different ($p<0.05$) between each time, for each type of alginate-dairy based microcapsule during the period of the analysis. ^{abcde}Means with different lowercase are significantly different ($p<0.05$) between each type of alginate-dairy based microcapsule, for a particular time of the analysis. For legend explanations see Table1.

Fig. 3. Stability of free and encapsulated *B. longum* subsp. *infantis* CCUG 52486 in simulated intestinal juice (pH 7.5) at 37 ºC for 120 min. Vertical lines represent standard deviations. ^{ABCDE}Means with different uppercase are significantly different ($p<0.05$) between each time, for each type of alginate-dairy based microcapsule during the period of the analysis. ^{abcde}Means with different lowercase are significantly different ($p<0.05$) between each type of alginate-dairy based microcapsule, for a particular time of the analysis. For legend explanations see Table1.

Fig. 4. Changes in the viable count of free and the encapsulated *B. longum* subsp. *infantis* CCUG 52486 during refrigerated storage (4 ºC) for 28 days. Vertical lines represent standard deviations. ^{ABCDE}Means with different uppercase are significantly different ($p<0.05$) between each time, for each type of alginate-dairy based microcapsule during the storage. ^{abcd}Means with different lowercase are significantly different ($p<0.05$) between each type of alginate-dairy based microcapsule, for a particular day of the storage period. For legend explanations see Table1.

570 Fig. 5. Changes in the viable counts free and encapsulated bacteria in goat milk at 4 ^{o}C for 28
571 days. Vertical lines represent standard deviations. ^{ABCDE}Means with different uppercase are
572 significantly different (*p<0.05*) between each time, for each type of alginate-dairy based
573 microcapsule during the storage. ^{abcd}Means with different lowercase are significantly different
574 (*p<0.05*) between each type of alginate-dairy based microcapsule, for a particular day of the
575 storage period. For legend explanations see Table1.

576

577

578

579

580

581

582

583

584

585

586 Table 1. Encapsulation yield and size of different microcapsules

Type of microcapsules	Size (mm)	Encapsulation yield (%)
SA	2.3 ± 0.4^{b}	95.6 ± 2.1^{a}
SACM	2.8 ± 0.3^{a}	94.9 ± 1.4^{a}
SAGM	3.1 ± 0.2^{a}	95.3 ± 1.6^{a}
SACH	2.4 ± 0.4^{b}	94.1 ± 2.7^{a}

587 ^{ab}Mean values (±standard deviation) within the same column not sharing a common superscript
588 differ significantly (P < 0.05). SA: microcapsules were prepared using alginate. SACM:
589 microcapsules were produced using alginate and cow milk at a ratio of 1.5:1 (v/v). SAGM:
590 microcapsules were produced using alginate and goat milk at a ratio of 1.5:1 (v/v). SACH:
591 microcapsules were prepared using alginate and casein hydrolysate at a ratio of 1.5:1 (v/v).

592

593

594 Table 2. Changes in the viability of free and encapsulated *B. longum* subsp. *infantis* CCUG
595 52486 in cow milk at 4 ºC for 28 days.

Type of capsule	Period of storage (days)				
	0	7	14	21	28
SA (log cfu g^{-1})	$8.53 \pm 0.09^{A\,a}$	$8.05 \pm 0.09^{A\,b}$	$7.38 \pm 0.09^{B\,c}$	$6.84 \pm 0.40^{B\,c}$	$6.03 \pm 0.04^{C\,c}$
SACM (log cfu g^{-1})	$8.57 \pm 0.11^{A\,a}$	$8.42 \pm 0.05^{AB\,a}$	$8.25 \pm 0.07^{BC\,b}$	$8.13 \pm 0.11^{C\,b}$	$7.07 \pm 0.15^{D\,b}$
SAGM (log cfu g^{-1})	$8.63 \pm 0.31^{A\,a}$	$8.59 \pm 0.17^{A\,a}$	$8.54 \pm 0.03^{A\,a}$	$8.52 \pm 0.06^{A\,a}$	$7.61 \pm 0.24^{B\,a}$
SACH (log cfu g^{-1})	$8.49 \pm 0.03^{A\,a}$	$7.63 \pm 0.06^{B\,c}$	$6.93 \pm 0.18^{C\,d}$	$6.38 \pm 0.38^{C\,c}$	$5.50 \pm 0.05^{D\,d}$
Free Cells (log cfu mL^{-1})	$8.65 \pm 0.12^{A\,a}$	$7.13 \pm 0.16^{B\,d}$	$5.10 \pm 0.07^{C\,e}$	$4.83 \pm 0.10^{C\,d}$	$4.38 \pm 0.29^{D\,e}$

596 ^{ABCD}Means in the same row without common letter differ significantly (*p<0.05*) for each type
597 of microcapsules. ^{abcde}Means in the same column for each type of microcapsule without
598 common letter differ significantly (*p<0.05*) for a particular day of storage. Data are expressed
599 as mean ± standard deviation. For legend explanations see

600 Table *1*.

601

602

603

604

605

606

607



608 Fig.1.

609

610

611

612

613

614



615

616 Fig. 2.

617

618

619

620

621

622

623

624

625

626

627



628

629 Fig. 3.

630

631



632

633 Fig. 4.

634

635



636

637 Fig. 5.

638

639

640

641

642